Inve US ▾
NONOVT

Novanta (NOVT) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· Information Technology· May 12, 2026

Source: earnings call transcript

Executive summary

Novanta Q1 FY26 — Strong Bookings and Organic Growth Acceleration

Novanta delivered a strong Q1 FY26, exceeding revenue expectations with accelerated organic growth and robust bookings, driven by new product momentum and strong commercial execution across all businesses. Despite temporary gross margin pressures from geopolitical factors, the company reaffirmed its full-year outlook, confident in its strategic investments in high-growth markets like AI-driven robotics and medical technologies, and its ongoing manufacturing footprint transformation.

Highlights

5
  • Revenue grew 10% reported and 3% organic, a step-up versus the prior quarter.

  • Bookings grew 37% year-over-year with a book-to-bill of 1.10.

  • Adjusted EBITDA grew 14% year-over-year, with margin expanding 70 basis points to 22%.

  • Operating cash flow increased 63% year-over-year to $52 million, representing over 200% cash flow conversion to net income.

  • New product revenue was up 50% year-over-year, raising the Vitality Index to 27% of sales.

Concerns

2
  • Adjusted gross margins were down 60 basis points year-over-year to 45.6% due to price/cost timing impact from higher freight, tariffs, and material costs.

  • The temporary inflation and tariff impact resulted in a $0.03 headwind to adjusted earnings per share.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 GAAP Revenue
$1,040 million to $1,055 million
high materiality
High
Full-year 2026 Reported Revenue Growth
greater than 7%
high materiality
High
Full-year 2026 Organic Revenue Growth
up to 6%
high materiality
High
Full-year 2026 Adjusted EBITDA
$245 million and $250 million
high materiality
High
Full-year 2026 Adjusted EBITDA Growth
11% to 13%
high materiality
High
Full-year 2026 Adjusted EPS
$3.50 to $3.65
high materiality
High
Full-year 2026 Adjusted EPS Growth
6% to 11%
high materiality
High
Full-year 2026 Cash Flow Conversion
100% or better
medium materiality
High
Q2 2026 GAAP Revenue
$259 million to $264 million
high materiality
High
Q2 2026 Organic Revenue Growth
6% to 8%
high materiality
High
Q2 2026 Reported Revenue Growth
up to 10%
high materiality
High
Q2 2026 Automation Enabling Technologies Segment Growth
10% to 12%
medium materiality
High
Q2 2026 Medical Solutions Segment Growth
high single-digit
medium materiality
High
Q2 2026 Medical Solutions - Precision Medicine Revenue Growth
mid-single-digit
low materiality
High
Q2 2026 Adjusted Gross Margins
45.5% to 46%
medium materiality
High
Q2 2026 R&D and SG&A Expenses
$74 million to $75 million
low materiality
High
Q2 2026 Adjusted EBITDA
$58 million and $62 million
high materiality
High
Q2 2026 Adjusted EBITDA Margin
approximately 23%
high materiality
High
Q2 2026 Non-GAAP Tax Rate
20% and 22%
low materiality
High
Q2 2026 Diluted Weighted Average Shares Outstanding
approximately 41 million shares
low materiality
High
Q2 2026 Diluted EPS
$0.81 to $0.86
high materiality
High
Q2 2026 Cash Flow Conversion
similar to the first quarter and on track to hitting cash conversion of greater than 100% of GAAP net income
medium materiality
High
Organic Growth
high single digits
high materiality
High
Gross Margin Step-up
in the second half
medium materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Automation Enabling Technologies
Segment revenue grew 7% year-over-year, better than expected. Adjusted gross margins were approximately 49%, roughly flat sequentially and down 60 basis points year-over-year due to tariff and cost inflation. New product revenue grew over 70% year-over-year, and customer design wins grew by 25%.
Book-to-bill: 1.15Bookings growth YoY: 35%New product revenue growth YoY: 70%Customer design wins growth: 25%Vitality Index: >20% of sales
—7%—49%
Automation Enabling Technologies - Precision Manufacturing
Revenue was up 6% year-over-year with double-digit bookings growth, continuing momentum from the prior quarter.
Bookings growth: double-digit
—6%——
Automation Enabling Technologies - Robotics & Automation
Revenue was up 7% year-over-year, and bookings were up 50%. The business sees a healthy outlook with solid demand for advanced robotic applications and increasing strength in semiconductor applications.
Bookings growth: 50%
—7%——
Medical Solutions
Segment revenue grew 15% year-over-year, better than expected. Adjusted gross margins were approximately 43%, roughly flat year-over-year but up 80 basis points sequentially. Strong productivity and higher margins from new product sales helped mitigate inflation impacts.
Book-to-bill: 1.04Bookings growth YoY: 40%New product sales growth YoY: 45%Vitality Index: >30% of salesCustomer design wins growth: strong double-digit rate
—15%—43%
Medical Solutions - Advanced Surgery
Experienced 11% growth year-over-year, driven by strong patient procedural growth rates and new product launches in second-generation insufflators.
—11%——
Medical Solutions - Precision Medicine
Sales grew by 18% year-over-year, mainly from the Keonn acquisition. The core business saw modest positive growth of 2% from products sold into hospital equipment markets.
—18%——

NOVT operating KPIs by quarter

NOVT operating KPIs stated on its earnings calls, by fiscal quarter
KPI Dec 2025 Q4 FY25This call Mar 2026 Q1 FY26 Jun 2026 Q2 FY26Change vs prior quarter
Book-to-bill
1.11 ratio Bookings surged 25% year-over-year and 12% sequentially with a book-to-bill of 1.11. Source: earnings call transcript
1.1 ratio Bookings grew 37% year-over-year with a book-to-bill of 1.10 on continued new product momentum and strong commercial execution. Source: earnings call transcript
—-0.9%
Vitality Index
24% New product sales in the fourth quarter grew over 80% year-over-year, raising the Vitality Index to 24% of sales. Source: earnings call transcript
27% In addition, new product sales grew over 50% year-over-year, raising the Vitality Index to 27% of sales. Source: earnings call transcript
~29% New product revenue grew by more than 50% in the quarter and is up over 60% year-to-date, lifting our vitality index to approximately 29% of sales from 21% a year ago. Source: earnings call transcript
—
Book-to-bill Automation Enabling Technologies
1.16 ratio The book-to-bill in this segment was 1.16 and bookings were up 33% year-over-year. Source: earnings call transcript
1.15 ratio The book-to-bill in this segment was 1.15 and bookings were up 35% year-over-year. Source: earnings call transcript
1.1 ratio The book-to-bill in this segment was 1.1 and bookings were up 18% year-over-year. Source: earnings call transcript
-4.3%
Book-to-bill Medical Solutions
1.07 ratio This segment saw a book-to-bill of 1.07 in the fourth quarter and bookings were up 17% year-over-year. Source: earnings call transcript
1.04 ratio This segment saw a book-to-bill of 1.04 in the quarter and bookings were up 40% year-over-year. Source: earnings call transcript
0.79 ratio This segment saw a book-to-bill of 0.79 in the second quarter and year-to-date had bookings growth of greater than 10% year-over-year. Source: earnings call transcript
-24%
Vitality Index Medical Solutions
<28% New product sales in the fourth quarter grew by nearly 80% year-over-year and the Vitality Index in this segment was nearly 28% of sales. Source: earnings call transcript
—
30%+ New product sales grew by nearly 50% year-over-year and the vitality index in this segment was above 30% of sales. Source: earnings call transcript
—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Orderbook & backlog

Bookings growth 37% Q1 FY26

YoY

All businesses had double-digit bookings growth versus the prior year.

Book-to-bill ratio 1.10 Q1 FY26

Supports a positive outlook and a growing backlog.

Backlog growing Q1 FY26

Majority of orders will ship in the next 12 months, with a typical 2-3 quarter lag between bookings and revenue.

Product announcements

ProductTypeDetails
Intelligent laser beam steering subsystemslaunch
Next-generation insufflatorsupdate

Deals & partnerships

Keonn Acquisition that drove growth in Precision Medicine business.

The Keonn acquisition was the main contributor to the 18% year-over-year sales growth in the Precision Medicine business.

NVIDIA Novanta joined the NVIDIA Halos AI Systems Inspection Lab.

Novanta's servo drives were selected for the NVIDIA Halos AI Systems Inspection Lab, recognizing their server drive technology leadership in safety validated AI-driven robotics. This certification provides credibility for OEMs using NVIDIA infrastructure.

Capital programs

Manufacturing Footprint Transformation underway

Benefit:gross margin step-up in the second half; better scale, stronger systems, deeper talent, full in-region for-region capability

Two facility closures are on track to be completed in the second quarter. This initiative aims to consolidate into fewer centers of manufacturing excellence.

Risks & headwinds

Gross margin pressure from geopolitical dynamics Q1 FY26, with expected impact into Q2

Adjusted gross margins down 60 basis points year-over-year to 45.6%; $0.03 headwind to adjusted EPS

Mitigation:Implementing new surcharges, product price increases, and cost reduction actions; repricing existing backlog; expecting tariffs to be muted in Q2 and positive price-cost ratio in Q3.

Macroeconomic complexity

Unquantified

Mitigation:Disciplined execution, strong product portfolio, and momentum to capitalize on demand in high-growth markets.

Trade dynamics, geopolitical tensions, and input cost volatility

Unquantified

Mitigation:Watching closely, implementing price and cost reduction actions, building safety stocks to insulate from supply tightness.

What to watch in Q2 FY26

Gross Margin Recovery

Q2 FY26 and H2 FY26
Current 45.6% (Q1 FY26)
Target 45.5% to 46% (Q2 FY26), stronger performance in H2

Why it matters

Gross margin trajectory is critical for profitability, especially after Q1 headwinds from tariffs and freight costs.

For adjusted gross margins, we expect the second quarter to come in at approximately 45.5% to 46%, roughly flat to modestly ahead of the first quarter. The sequential improvement will be moderate as our surcharging adjustments, price increases and cost reduction initiatives fully take hold. That said, we expect these actions to drive meaningful stronger margin performance in the second half of the year as their full benefit is realized.

Find out whether NOVT delivers this. Inve re-checks your case every morning.

Q&A highlights

Clarification on the 15% of revenue attributed to DUV, EUV lithography, board drilling, and other AI-related applications; whether it's all semiconductor.

Matthijs clarified that the 15% is a collective of applications within Precision Manufacturing and Robotics & Automation, driven by GenAI infrastructure investments, not solely semiconductor. It includes DUV/EUV lithography, GPU drilling, advanced packaging, probe card production, and metrology for advanced wafer fab nodes, all requiring high precision.

“It includes current core business to deep UV, EUV lithography, new product ramps in deep UV and EUV lithography, GPU drilling, but also advanced manufacturing aspects like probe card production, which is used for GPU testing.”

asked by Lee Jagoda · answered by Matthijs Glastra

2 min read 6 chapters

Detailed narrative

AI-Driven Market Opportunities

Novanta is capitalizing on strong demand in AI infrastructure, semiconductors, advanced industrial, and medical markets, with new product innovations driving record bookings and design wins. The company estimates its exposure to GenAI data center boom applications at approximately 15% of total Q1 revenue, growing 20% year-over-year, with expectations for acceleration throughout the year.

This exposure spans DUV and EUV lithography, advanced packaging, probe card production, precision robotics, GPU drilling, and metrology for advanced semiconductor wafer nodes.

Strategic Growth Pillars

The long-term strategy focuses on winning in high-growth end markets with durable secular tailwinds, including AI-driven Robotics & Automation, minimally invasive and robotic surgery, digital and AI-driven manufacturing, and Precision Medicine. These markets represent a $4 billion incremental opportunity by 2030. Novanta invests in growth platforms such as next-generation insufflators, robotic surgery technologies, intelligent physical AI solutions, and intelligent subsystems for laser beam steering.

Manufacturing Footprint Transformation

The company is making steady progress on its regional manufacturing initiative, with two facility closures on track to be completed in the second quarter. This transformation aims to consolidate into fewer centers of manufacturing excellence, gaining better scale, stronger systems, deeper talent, and full in-region for-region capability.

This initiative is expected to support a gross margin step-up in the second half of the year and sustainably expand both gross margins and profitability.

Gross Margin Headwinds and Mitigation

First quarter adjusted gross margins were impacted by a price/cost timing issue, primarily due to rapidly shifting geopolitical dynamics that led to higher freight, tariff costs (e.g., aluminum tariffs increasing from 25% to 50%), and material costs. These changes outpaced the company's immediate ability to surcharge customers and reprice orders.

Management is actively implementing new surcharges, product price increases, and cost reduction actions, expecting these to fully take hold and drive stronger margin performance in the second half of the year.

Capital Allocation Strategy

While acquisitions remain the top capital allocation priority, Novanta opportunistically repurchased approximately $18 million worth of company stock in the first quarter. The company maintains a strong balance sheet with a negative net debt position of $139 million and a gross leverage ratio of 1.1x.

Novanta has a deep and active pipeline of mid- to larger acquisition opportunities in medical technologies, medical consumables, embedded software, and adjacencies like bioprocessing, with plans to deploy meaningful capital this year.

NVIDIA Partnership and Robotics

Novanta's servo drives were selected to join the NVIDIA Halos AI Systems Inspection Lab, a recognition of its technology leadership in safety-validated AI-driven robotics. This certification within the NVIDIA ecosystem adds significant credibility for OEMs in humanoid and warehouse automation applications.

While these applications are still in the prototype phase, the partnership is expected to drive more meaningful prototype orders and future adoption, with a more pronounced impact anticipated in 2027.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.